Li Qi, Li Linyan, Li Qiqiong, Wang Junqiao, Nie Shaoping, Xie Mingyong
State Key Laboratory of Food Science and Technology, China-Canada Joint Lab of Food Science and Technology (Nanchang), Key Laboratory of Bioactive Polysaccharides of Jiangxi Province, Nanchang University, Nanchang 330047, China.
Center for Microbial Ecology and Technology (CMET), Faculty of Bioscience Engineering, Ghent University, 9000 Ghent, Belgium.
Foods. 2022 Apr 9;11(8):1084. doi: 10.3390/foods11081084.
The incidence of inflammatory bowel disease (IBD) has increased in recent years. Considering the potential side effects of conventional drugs, safe and efficient treatment methods for IBD are required urgently. Natural polysaccharides (NPs) have attracted considerable attention as potential therapeutic agents for IBD owing to their high efficiency, low toxicity, and wide range of biological activities. Intestinal microbiota and their fermentative products, mainly short-chain fatty acids (SCFAs), are thought to mediate the effect of NPs in IBDs. This review explores the beneficial effects of NPs on IBD, with a special focus on the role of intestinal microbes. Intestinal microbiota exert alleviation effects via various mechanisms, such as increasing the intestinal immunity, anti-inflammatory activities, and intestinal barrier protection via microbiota-dependent and microbiota-independent strategies. The aim of this paper was to document evidence of NP-intestinal microbiota-associated IBD prevention, which would be helpful for guidance in the treatment and management of IBD.
近年来，炎症性肠病（IBD）的发病率有所上升。鉴于传统药物的潜在副作用，迫切需要安全有效的IBD治疗方法。天然多糖（NPs）因其高效、低毒和广泛的生物活性，作为IBD的潜在治疗剂受到了广泛关注。肠道微生物群及其发酵产物，主要是短链脂肪酸（SCFAs），被认为介导了NPs在IBD中的作用。本综述探讨了NPs对IBD的有益作用，特别关注肠道微生物群的作用。肠道微生物群通过多种机制发挥缓解作用，例如通过微生物群依赖和微生物群非依赖策略增强肠道免疫力、抗炎活性和肠道屏障保护。本文的目的是记录NP-肠道微生物群相关的IBD预防证据，这将有助于指导IBD的治疗和管理。
